生物技术公司INmune Bio Inc. 已正式宣布，其针对早期阿尔茨海默病的在研疗法Xpro1595，获得了美国食品药品监督管理局（FDA）对其综合2B/3期注册路径的认可。这一关键进展标志着该药物的临床开发计划向前迈出了重要一步，为后续的注册申请奠定了基础。
生物技术公司INmune Bio Inc. 已正式宣布，其针对早期阿尔茨海默病的在研疗法Xpro1595，获得了美国食品药品监督管理局（FDA）对其综合2B/3期注册路径的认可。这一关键进展标志着该药物的临床开发计划向前迈出了重要一步，为后续的注册申请奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.